Morning Movers Gapping up $美國航空(AAL.US)$stock increased by 5.2% as the company predicted profits for the current quarter that are largely above expectations, fueled by a resurgence in business travel and the prospect of strong demand during the summer season. $福特汽車(F.US)$stock climbed 1.1% due to robust first-quarter earnings, a strong showing from its commercial vehicle division, rising hybrid vehicle sale...
Earnings Preview Next week's earnings reports from major technology companies might provide a boost to a weakening market, or at the very least, offer investors insight into future stock trends. $特斯拉(TSLA.US)$is set to release its earnings on Tuesday, followed by$Meta Platforms(META.US)$on Wednesday. The week continues with a significant day on Thursday, as$谷歌-C(GOOG.US)$, the parent company of Google...
$默沙東(MRK.US)$'s $11.5 bil bet on Acceleron in 2021 pays off w/ FDA approval of Wenrevair for PAH, When deal closed in 2021 analysts were projecting peak sales of $2.2 bil for sotatercept (Wenrevair), now estimates are as high as $5-$7.5 bil, Looks like MRK got a great deal but Wenrevair would still only cover about 20%-25% of Keytruda's $25 bil in rev from LOE in 2028, MRK's made 4 other big acquisitions since 2021: $680 mil for $HARP, $610 mil for Caraway, $1.3 bil for Imago and the big...
Analysts predict Winrevair could solve half of the revenue problem caused by Keytruda's loss of exclusivity. Its approval without serious safety warnings or restrictions is seen as a testament to Merck's strategic efforts.
默沙東股票討論區
專欄Today's Morning Movers and Top Ratings: META, IBM, AAL, CAT and More
Gapping up
$美國航空(AAL.US)$ stock increased by 5.2% as the company predicted profits for the current quarter that are largely above expectations, fueled by a resurgence in business travel and the prospect of strong demand during the summer season.
$福特汽車(F.US)$ stock climbed 1.1% due to robust first-quarter earnings, a strong showing from its commercial vehicle division, rising hybrid vehicle sale...
專欄What to Expect in the Week Ahead (TSLA, META, GOOG, MSFT Earnings; PCE Inflation)
Next week's earnings reports from major technology companies might provide a boost to a weakening market, or at the very least, offer investors insight into future stock trends.
$特斯拉(TSLA.US)$ is set to release its earnings on Tuesday, followed by $Meta Platforms(META.US)$ on Wednesday. The week continues with a significant day on Thursday, as $谷歌-C(GOOG.US)$ , the parent company of Google...
PPI
That said, this new set data is still showing that inflation is very sticky. The final mile towards Fed’s 2% is going to be a tough one
$Marathon Digital(MARA.US)$$Palantir(PLTR.US)$$Arm Holdings(ARM.US)$$iShares Bitcoin Trust(IBIT.US)$$超微電腦(SMCI.US)$$第一共和銀行(FRCB.US)$$SPDR道瓊斯指數ETF(DIA.US)$$默沙東(MRK.US)$$聯合健康(UNH.US)$$達美航空(DAL.US)$$波音(BA.US)$$DraftKings(DKNG.US)$$Snap Inc(SNAP.US)$$勞氏(LOW.US)$
FDA PDUFA Update…
$Akebia Therapeutics(AKBA.US)$ : Approved 🎉
⇒ Vafseo (Vadadustat)
⇒ Anemia due to CKD
⇒ NDA
⇒ PDUFA: 3/27/24
$默沙東(MRK.US)$ : Approved 🎉
⇒ WINREVAIR (sotatercept)
⇒ Pulmonary arterial hypertension
⇒ BLA
⇒ PDUFA: 3/26/24
$阿斯利康(AZN.US)$ : Approved 🎉
⇒ Ultomiris (ravulizumab)
⇒ NMOSD
⇒ sBLA
$再生元製藥公司(REGN.US)$ : CRL 🙁
⇒ Odronextamab
⇒ r/r FL and r/r DLBCL
⇒ BLA
⇒ PDUFA: 3/31/24
📌 This week’s PDUFAs: 🚨
$阿斯利康(AZN.US)$ : 🤔
⇒...
Updated Complete & Utter M&A Guesses Purely for Entertainment Purposes:
$默沙東(MRK.US)$ x $Immunovant(IMVT.US)$
$禮來(LLY.US)$ x $Cytokinetics(CYTK.US)$ (and soon)
$再生元製藥公司(REGN.US)$ x $Apellis Pharmaceuticals(APLS.US)$ (panache & brash)
$吉利德科學(GILD.US)$ x %$Madrigal Pharmaceuticals(MDGL.US)$ (liver king)
$施貴寶(BMY.US)$ x $Iovance Biotherapeutics(IOVA.US)$ (cell Tx boost needed)
$禮來(LLY.US)$ x $Merus(MRUS.US)$ (partner n...
When deal closed in 2021 analysts were projecting peak sales of $2.2 bil for sotatercept (Wenrevair), now estimates are as high as $5-$7.5 bil,
Looks like MRK got a great deal but Wenrevair would still only cover about 20%-25% of Keytruda's $25 bil in rev from LOE in 2028,
MRK's made 4 other big acquisitions since 2021: $680 mil for $HARP, $610 mil for Caraway, $1.3 bil for Imago and the big...
🥇 First-in-class Tx for adults with pulmonary arterial hypertension (PAH WHO Group 1)
📌 significantly improved exercise capacity & multiple important secondary outcome measures
ℹ️ WINREVAIR™
⇒ injection for SC use 💉
⇒ previously granted Breakthrough Therapy Designation
⇒ BLA w/ assigned PDUFA 3/26/24
$SPDR 標普500指數ETF(SPY.US)$ +0.51% 🟩
$納指100ETF-Invesco QQQ Trust(QQQ.US)$ +0.54% 🟩
$道瓊斯指數(.DJI.US)$ +0.67% 🟩
$iShares羅素2000指數ETF(IWM.US)$ +1.01% 🟩
Stocks on move: $Robinhood(HOOD.US)$ +4.5%, $默沙東(MRK.US)$ +4.6%, $迪士尼(DIS.US)$ +1.5%, $Enphase Energy(ENPH.US)$ +4.9%, $特朗普媒體科技集團(DJT.US)$ +19%, $MicroStrategy(MSTR.US)$ + 5.7%, $邁威爾科技(MRVL.US)$ +4.90%, $nCino(NCNO.US)$ +16%, $特斯拉(TSLA.US)$ +0.4% (...
暫無評論